<DOC>
	<DOCNO>NCT02020434</DOCNO>
	<brief_summary>RPX7009 ( beta-lactamase inhibitor ) study combination carbapenem ( RPX2014 ) treat bacterial infection , include due multi-drug resistant bacteria .</brief_summary>
	<brief_title>The Safety Pharmacokinetics Carbavance™ ( RPX2014/RPX7009 ) Subjects With Renal Insufficiency</brief_title>
	<detailed_description>The worldwide spread resistance antibiotic among Gram-negative bacteria , particularly member ESKAPE group pathogen , result crisis treatment hospital acquire infection . In particular , recent dissemination serine carbapenemase ( e.g. , KPC ) Enterobacteriaceae US hospital pose considerable threat carbapenems member beta-lactam class antimicrobial agent . Rempex develop fix combination antibiotic carbapenem ( RPX2014 ) plus new beta-lactamase inhibitor ( RPX7009 ) activity serine beta-lactamase , include KPC . This Phase 1 study ass safety , tolerability pharmacokinetics intravenous RPX2014 RPX7009 , administer combination subject vary degree renal insufficiency .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Males female age 18 80 year age 2 . Willing abstain alcohol 48 hour prior dose discharge 3 . Normal volunteer first match age ( ± 10 year ) , BMI ( ± 20 % ) , gender mean value moderate renal insufficiency group . 4 . Have negative test result HBsAg , antiHCV antibody antiHIV antibody . 5 . Voluntarily consent participate study 6 . Sexually abstinent agree use two approve method contraception . 7 . Assessment renal insufficiency assignment study group base measurement eGFR calculated MDRD equation Screening Visit determine eligibility . 1 . Unstable new medical condition ( e.g. , cardiovascular , respiratory , hepatic , renal , gastrointestinal , autoimmune , endocrine , neurological disorder ) 2 . Hypersensitivity idiosyncratic reaction βlactam antibiotic ( e.g . penicillin , cephalosporin , carbapenems ) 3 . History clinically significant seizure , head injury , meningitis . 4 . Current evidence history malignancy , exclude basal cell carcinoma , 2 year prior Day 1 evidence recurrence . 5 . Females pregnant , lactating , positive pregnancy test 6 . Previously receive dose Carbavance ( RPX2014/RPX7009 ) . 7 . Current participation another investigational study participation another investigational clinical study within 30 day prior Screening Visit . 8 . Blood donation significant blood loss ( i.e. , &gt; 500 mL ) within 56 day prior Day 1 . 9 . Plasma platelet donation within 14 day prior Day 1 . 10 . Any acute illness require antibiotic drug therapy within 30 day prior Day 1 febrile illness within 7 day prior Day 1 . 11 . Vigorous exercise 48 hour prior Day 1 day discharge study . 12 . Positive urine drug/alcohol test Screening Visit Day 1 13 . Concurrent use medication know affect elimination serum creatinine ( e.g. , trimethoprim/sulfamethoxazole [ Bactrim® ] cimetidine [ Tagamet® ] ) competitor renal tubular secretion ( e.g. , probenecid ) within 30 day prior first dose study drug 14 . Abnormal clinically significant finding physical examination , medical history , serum chemistry , hematology , urinalysis 15 . Use prescription nonprescription drug , vitamin , grapefruit/grapefruit juice dietary herbal supplement within 14 day prior Day 1 . 1 . Oral contraceptive permit birth control . 2 . Acetaminophen ( ≤ 1 g/day ) lowdose ASA ( i.e. , ≤ 325 mg per day ) permit . 16 . Currently receive hemodialysis peritoneal dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>